Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
- 1 November 2002
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 47 (5) , 692-700
- https://doi.org/10.1067/mjd.2002.124698
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- CD69, HLA-DR and the IL-2R Identify Persistently Activated T Cells in Psoriasis Vulgaris Lesional Skin: Blood and Skin Comparisons by Flow CytometryJournal of Autoimmunity, 2000
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory moleculeEuropean Journal of Immunology, 1995
- B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapyCell, 1995
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- “Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4Nature Biotechnology, 1992
- A new member of the immunoglobulin superfamily—CTLA-4Nature, 1987
- Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytesImmunology Today, 1986
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978
- A Theory of Self-Nonself DiscriminationScience, 1970